Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

Results 1 - 20 of 37 : 1 2 Next »

Recs

0
Member Avatar sullyz0r (73.79) Submitted: 11/25/2014 10:22:45 PM : Outperform Start Price: $20.38 CLDX Score: -6.79

A bit late on this one, but better late than later.

Recs

1
Member Avatar Gilcon (< 20) Submitted: 10/19/2014 11:05:02 AM : Outperform Start Price: $14.93 CLDX Score: +19.27

Pipeline of opportunity for CLDX.

Recs

0
Member Avatar DLester78 (73.81) Submitted: 9/29/2014 6:00:35 PM : Outperform Start Price: $13.70 CLDX Score: +33.64

oversold... tons of risk, could be no reward.

Recs

0
Member Avatar asilverp (60.28) Submitted: 8/28/2014 12:25:20 PM : Underperform Start Price: $15.94 CLDX Score: -15.53

p/s of over 500 and losing money.

Recs

0
Member Avatar stockgripes (99.18) Submitted: 8/21/2014 4:05:09 PM : Outperform Start Price: $14.30 CLDX Score: +28.71

time to switch the thumb again

Recs

0
Member Avatar wimmreuter (29.83) Submitted: 9/26/2013 2:22:01 PM : Outperform Start Price: $35.18 CLDX Score: -68.20

Coming down from the high 80s and now slowly being successful with their medication is the a long way to go but rewards are coming.

Recs

0
Member Avatar Teknowizz (92.86) Submitted: 9/25/2013 3:06:12 AM : Outperform Start Price: $34.48 CLDX Score: -66.87

OK let's see whether she will run some more.
Really stopped this too early in order to bank the +300 run :)

Recs

2
Member Avatar bignr15 (< 20) Submitted: 7/7/2013 3:36:34 PM : Outperform Start Price: $21.40 CLDX Score: -37.62

Huge Growth Potential, could hit $60 in 2 years. Will be lots of ups and downs, so have long term view on this one.

Recs

0
Member Avatar FoolsLint (< 20) Submitted: 7/6/2013 4:59:20 PM : Outperform Start Price: $21.40 CLDX Score: -37.62

The demand for cancer cure. The success this company is having . The effect that this company is having on breast cancer is a very good start.

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 6/11/2013 7:15:03 AM : Outperform Start Price: $15.14 CLDX Score: -1.50

Pipeline is strong and competition is minimal.

Recs

1
Member Avatar MyManDon1 (< 20) Submitted: 7/20/2012 11:38:21 AM : Outperform Start Price: $5.38 CLDX Score: +200.71

1) market cap of only $300MM
2) has cash on hand to get through PIII with leading drugs
3) owns most important drugs outright keeping significant potential for homegrown profits inhouse and/or leaving room for partnership and/or full buyout
4) multiple drugs in pII providing cushion agains setback (i.e. limited downside risk)
5) management/science presentations exhibit sound planning and strategy that is needed to succeed
6) partnership activity is picking up due to patent cliffs at many big pharmas

Recs

1
Member Avatar rangarajud (52.71) Submitted: 5/16/2012 5:31:51 PM : Outperform Start Price: $4.47 CLDX Score: +267.82

great stock with huge pipeline and promising drug status on May 23rd 2012 will send this stock north of 7$.

Recs

1
Member Avatar stainsolution (43.12) Submitted: 4/24/2012 3:24:49 PM : Outperform Start Price: $3.96 CLDX Score: +326.60

ASCO run---might be a little early here.

Recs

1
Member Avatar RBuskey106 (50.71) Submitted: 3/21/2012 8:22:30 PM : Outperform Start Price: $4.77 CLDX Score: +249.18

ASCO pick

Recs

0
Member Avatar solanZRaider (< 20) Submitted: 5/16/2011 12:43:10 PM : Outperform Start Price: $3.52 CLDX Score: +381.02

irishred1

Recs

0
Member Avatar Khatte (< 20) Submitted: 4/11/2011 8:54:38 PM : Outperform Start Price: $4.10 CLDX Score: +304.68

It appears that CLDX is entering phase III of clinical trials on it's new immune based cancer treatments with strong results in earlier phases.

Recs

0
Member Avatar sjc40 (33.07) Submitted: 2/18/2011 6:57:39 PM : Outperform Start Price: $3.60 CLDX Score: +368.43

as a physician i think this is the best of all biotech

Recs

0
Member Avatar julianna8 (< 20) Submitted: 10/7/2010 4:34:28 PM : Outperform Start Price: $4.32 CLDX Score: +260.01

taking a gamble on this one.

Recs

1
Member Avatar KattyKay (87.71) Submitted: 10/6/2010 3:12:13 PM : Outperform Start Price: $4.50 CLDX Score: +242.04

Celldex Therapeutics, Inc. has strong science underlying it's drug candidates. The therapeutic use of a vaccine to 'teach' the immune system to control or remove the cancer cells is a unique niche that has few other candidate drugs. The clinical trial data is quite promising that this approach works in humans as well as in animals. Given the good clinical data so far, a new clinical development partner will be easier to find and negotiate with. This pick is a long-term pick though.

Recs

1
Member Avatar TMFBreakerJava (99.49) Submitted: 10/5/2010 3:42:08 PM : Outperform Start Price: $4.74 CLDX Score: +221.47

Startlingly good results released today in a glioblastoma drug trial. This is a vaccine style treatment, a domain which has been pursued without success until recent DNDN breakthrough in prostate cancer

Results 1 - 20 of 37 : 1 2 Next »

Featured Broker Partners


Advertisement